JPRN-UMIN000001863
Completed
Phase 2
A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. - First-Line Gefitinib for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.
Central Japan Lung Study Group0 sites19 target enrollmentApril 8, 2009
Conditionson-Small-Cell Lung Cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-Small-Cell Lung Cancer
- Sponsor
- Central Japan Lung Study Group
- Enrollment
- 19
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Active infection, uncontrolled heart disease or diabetes mellitus 2\) Interstitial pneumonia / pulmonary fibrosis on computed tomography scan 3\) Massive pleural or pericardial effusion, or ascites 4\) Superior vena cava syndrome 5\) Symptomatic brain metastases 6\) Severe drug allergy 7\) Previous radiotherapy to the primary tumor 8\) Postoperative adjuvant therapy 9\) Other concurrent active malignancy 10\) Pregnant or breast\-feeding woman
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15
Completed
Phase 2
phase II study of gefitinib as a first-line therapy in elderly patients with lung adenocarcinoma.JPRN-C000000136West Japan Oncology Group30
Completed
Phase 2
A Phase II Study of Gefitinib Monotherapy as First-Line Treatment for Elderly Patients with Stage IIIB /IV Adenocarcinoma of the LungJPRN-UMIN000006144Central Japan Lung Study Group32
Completed
Phase 2
A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positivenon-small cell lung cancerwith high-risk factorsnon-small cell lung cancerJPRN-UMIN000004822Kanagawa Cancer Center37
Recruiting
Phase 1
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70